Subscribe To
CDXC / ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
CDXC News
By Business Wire
October 31, 2023
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy more_horizontal
By Seeking Alpha
August 9, 2023
ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media more_horizontal
By Business Wire
August 2, 2023
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced th more_horizontal
By Business Wire
May 2, 2023
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy more_horizontal
By Seeking Alpha
March 8, 2023
ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, more_horizontal
By Zacks Investment Research
March 8, 2023
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold more_horizontal
By Business Wire
February 27, 2023
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy more_horizontal
By Zacks Investment Research
December 19, 2022
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical mea more_horizontal